Latest Ratios: P/E Ratio 14.9x · EV/EBITDA 10.4x · ROE 166.3%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $11.8B | $14.9B | $17.0B | $19.7B | $17.5B | $22.9B | $28.0B | $19.9B | $17.8B | $17.5B | $18.2B |
| Enterprise Value | $14.5B | $17.6B | $19.7B | $22.3B | $20.4B | $25.7B | $30.3B | $22.4B | $20.1B | $19.3B | $20.1B |
| P/E Ratio → | 14.92 | 18.42 | 60.65 | 132.53 | 37.80 | 32.24 | 29.85 | 24.23 | 21.64 | 25.00 | 28.13 |
| P/S Ratio | 1.66 | 2.10 | 2.40 | 2.67 | 2.46 | 3.12 | 4.17 | 3.20 | 2.91 | 2.93 | 3.16 |
| P/B Ratio | 25.08 | 30.96 | 34.62 | 50.90 | 23.96 | 38.69 | 30.84 | 35.55 | 24.51 | 32.34 | 61.37 |
| P/FCF | 15.45 | 19.61 | 35.26 | 21.24 | 32.65 | 24.24 | 21.68 | 25.28 | 22.82 | 27.52 | 30.08 |
| P/OCF | 11.99 | 15.21 | 24.51 | 17.06 | 22.22 | 17.95 | 18.12 | 20.03 | 18.27 | 20.20 | 23.43 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.48 | 2.78 | 3.02 | 2.87 | 3.51 | 4.50 | 3.61 | 3.29 | 3.23 | 3.50 |
| EV / EBITDA | 10.35 | 12.62 | 17.14 | 20.98 | 22.16 | 17.78 | 20.95 | 17.41 | 15.59 | 15.02 | 16.33 |
| EV / EBIT | 12.27 | 14.96 | 39.39 | 65.42 | 28.96 | 25.93 | 23.68 | 20.13 | 17.91 | 17.32 | 18.91 |
| EV / FCF | — | 23.17 | 40.86 | 23.99 | 38.11 | 27.25 | 23.42 | 28.56 | 25.83 | 30.31 | 33.23 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 45.0% | 45.0% | 42.6% | 38.9% | 35.0% | 43.3% | 45.4% | 43.6% | 43.5% | 44.6% | 45.2% |
| Operating Margin | 16.6% | 16.6% | 12.9% | 11.2% | 9.8% | 16.9% | 18.8% | 17.8% | 18.4% | 18.8% | 18.5% |
| Net Profit Margin | 11.4% | 11.4% | 3.9% | 2.0% | 6.5% | 9.7% | 14.0% | 13.2% | 13.4% | 11.7% | 11.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 166.3% | 166.3% | 63.6% | 26.7% | 69.9% | 94.7% | 128.0% | 127.6% | 129.8% | 167.1% | 312.3% |
| ROA | 14.3% | 14.3% | 4.8% | 2.5% | 7.4% | 11.3% | 16.6% | 16.1% | 17.1% | 15.4% | 14.9% |
| ROIC | 27.7% | 27.7% | 22.4% | 18.8% | 14.7% | 28.1% | 30.2% | 26.7% | 31.3% | 37.2% | 38.7% |
| ROCE | 30.2% | 30.2% | 22.3% | 19.7% | 16.1% | 27.3% | 29.9% | 29.4% | 34.0% | 39.2% | 37.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 5.98 | 5.98 | 5.90 | 7.54 | 4.26 | 5.35 | 3.44 | 4.80 | 3.42 | 4.05 | 7.78 |
| Debt / EBITDA | 2.06 | 2.06 | 2.52 | 2.75 | 3.37 | 2.19 | 2.16 | 2.08 | 1.92 | 1.71 | 1.88 |
| Net Debt / Equity | — | 5.63 | 5.49 | 6.59 | 4.01 | 4.81 | 2.48 | 4.60 | 3.24 | 3.28 | 6.43 |
| Net Debt / EBITDA | 1.94 | 1.94 | 2.35 | 2.41 | 3.17 | 1.97 | 1.56 | 2.00 | 1.82 | 1.38 | 1.55 |
| Debt / FCF | — | 3.57 | 5.59 | 2.75 | 5.46 | 3.01 | 1.74 | 3.27 | 3.02 | 2.79 | 3.15 |
| Interest Coverage | 11.67 | 11.67 | 4.86 | 3.31 | 7.26 | 10.68 | 13.74 | 12.25 | 14.24 | 13.60 | 12.99 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.84 | 0.84 | 1.03 | 0.95 | 0.97 | 0.89 | 1.42 | 0.91 | 1.09 | 0.84 | 0.95 |
| Quick Ratio | 0.57 | 0.57 | 0.63 | 0.59 | 0.54 | 0.52 | 1.10 | 0.55 | 0.67 | 0.58 | 0.67 |
| Cash Ratio | 0.09 | 0.09 | 0.13 | 0.19 | 0.10 | 0.16 | 0.61 | 0.08 | 0.11 | 0.23 | 0.26 |
| Asset Turnover | — | 1.28 | 1.23 | 1.24 | 1.15 | 1.16 | 1.08 | 1.21 | 1.21 | 1.31 | 1.28 |
| Inventory Turnover | 7.48 | 7.48 | 6.39 | 6.49 | 6.11 | 5.53 | 8.08 | 6.84 | 6.84 | 7.20 | 7.13 |
| Days Sales Outstanding | — | 42.18 | 35.76 | 33.99 | 34.97 | 30.03 | 35.19 | 37.06 | 35.76 | 34.53 | 36.05 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 5.0% | 4.0% | 3.5% | 3.0% | 3.3% | 2.4% | 1.9% | 2.5% | 2.5% | 2.4% | 2.2% |
| Payout Ratio | 74.3% | 74.3% | 212.5% | 391.3% | 123.6% | 78.6% | 56.8% | 59.8% | 54.7% | 58.8% | 61.4% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 6.7% | 5.4% | 1.6% | 0.8% | 2.6% | 3.1% | 3.4% | 4.1% | 4.6% | 4.0% | 3.6% |
| FCF Yield | 6.5% | 5.1% | 2.8% | 4.7% | 3.1% | 4.1% | 4.6% | 4.0% | 4.4% | 3.6% | 3.3% |
| Buyback Yield | 2.8% | 2.2% | 0.0% | 0.0% | 0.1% | 4.0% | 0.9% | 3.3% | 1.5% | 1.0% | 1.4% |
| Total Shareholder Yield | 7.8% | 6.3% | 3.5% | 3.0% | 3.4% | 6.4% | 2.8% | 5.8% | 4.1% | 3.4% | 3.6% |
| Shares Outstanding | — | $124M | $125M | $124M | $124M | $127M | $128M | $130M | $132M | $132M | $132M |
Excessive leverage and liquidity
According to current market data, CLX trades at a P/E of 14.96, which appears to discount the company's historical defensive premium when compared to the significantly higher 32.91 P/E multiple commanded by Church & Dwight, suggesting market skepticism regarding the durability of Clorox's long-term growth trajectory.
The current valuation multiples imply that investors are pricing in a lower growth profile than the company's historical averages might suggest. Given the volatility in recent earnings and the erosion of the equity base, the current P/E may not fully reflect the risks associated with the company's elevated debt levels and inconsistent cash flow generation.
Based on reported financial statements, the company's ROIC has trended downward from 10.4% in 2025Q4 to 6.8% in 2026Q3, indicating that the firm is struggling to generate adequate returns on its invested capital as it navigates a challenging post-cyberattack operational environment and persistent inflationary cost pressures.
The decline in ROIC suggests that the company's core business units are failing to compound capital effectively, likely due to the combination of stagnant asset turnover and margin compression. This trend warrants further investigation into whether the current capital allocation strategy is prioritizing shareholder returns over the necessary reinvestment required to maintain its competitive moat.
As reported in recent filings, the company's cash conversion cycle has exhibited extreme volatility, with the CCC shifting from -77 days in 2025Q3 to a lack of available data in 2026Q3, highlighting significant difficulties in optimizing inventory and accounts payable in the current retail environment.
The inability to maintain a stable cash conversion cycle suggests that the company's supply chain and trade credit management are under stress. Investors should monitor whether these inefficiencies are structural or temporary, as they directly impact the firm's ability to generate free cash flow during periods of high commodity price volatility.
According to the latest quarterly data, the company's debt-to-equity ratio has surged to an alarming 48.76 in 2026Q3, a stark contrast to the 5.98 reported in 2025Q4, indicating that the firm's reliance on external financing has reached a level that may severely constrain future strategic initiatives.
This rapid escalation in leverage, coupled with a current ratio consistently below 1.0, suggests a vulnerable balance sheet that lacks the liquidity buffer typically expected of a consumer defensive firm. The company's interest coverage ratio, while currently positive, remains sensitive to any further deterioration in operating income, which could jeopardize its ability to service debt.
As reported in recent financial disclosures, the market's common reliance on headline EPS for Clorox is fundamentally flawed, as it obscures the significant volatility in net income and the impact of non-recurring items like the 2023 cybersecurity breach and ongoing restructuring charges.
Investors should instead focus on free cash flow conversion and normalized operating margins to gauge the true earning power of the business. Relying on EPS in this context ignores the underlying cash flow volatility and the erosion of the equity base, which are more critical indicators of the company's long-term financial health.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CLX stock.
The Clorox Company's current P/E ratio is 14.9x. The historical average is 32.9x. This places it at the 10th percentile of its historical range.
The Clorox Company's current EV/EBITDA is 10.4x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 13.6x.
The Clorox Company's return on equity (ROE) is 166.3%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 115.9%.
Based on historical data, The Clorox Company is trading at a P/E of 14.9x. This is at the 10th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
The Clorox Company's current dividend yield is 4.98% with a payout ratio of 74.3%.
The Clorox Company has 45.0% gross margin and 16.6% operating margin. Operating margin between 10-20% is typical for established companies.
The Clorox Company's Debt/EBITDA ratio is 2.1x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.